ONCOSIL MEDICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0130 AUD | 0.00% |
|
+8.33% | +44.44% |
| Aug. 30 | OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director | CI |
| Aug. 30 | OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2024 | CI |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: June | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Device development for new medical treatments | 3.63M | 2.76M | 1.3M | 1.06M | 1.47M | |||||
Total Assets | 11.67M | 24.06M | 14.15M | 13.07M | 11.47M | |||||
Interest Expense | - | -11.08K | -15.75K | -19.62K | -10.9K | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -14.83K | -20.72K | -54K | -5.83K | -57.82K | |||||
EBT | -8.57M | -4.26M | -10.43M | -10.73M | -11.34M | |||||
D&A | 38.62K | 149K | 185K | 192K | 176K | |||||
Net Income | -8.57M | -4.26M | -10.43M | -10.73M | -11.34M |
Geographical Revenue Distribution History
| Fiscal Period: June | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
APAC (Australia and New Zealand) | - | - | 213K | 232K | 256K | |||||
Europe | - | - | - | - | 112K |
- Stock Market
- Equities
- OSL Stock
- Financials OncoSil Medical Limited
- Business Segments